News|Videos|January 14, 2025

Estimating the AUC for Vancomycin Using Non Trapezoidal Equations

In the second part of our conversation, Abdulwhab Shremo Msdi, PharmD, discusses using this methodology.

In the first part of the interview with Msdi, he discussed AUC-based monitoring for vancomycin and its adoption by institutions and its value in dosing. (See the article below.) 

Read more: Looking at the Slow Adoption of AUC-Based Monitoring for Vancomycin

In this segment, Msdi talks about using a unique approach that estimates the AUC for vancomycin using non trapezoidal equations. He says the equations are not novel but rather uncommon and he discovered them during his fellowship.

“I think it's an attention issue—not complexity—because they are not very complex to do, but there is just not much published for us pharmacists to see how to use them," Msdi said.

He also likes this approach as it helps describe drug kinetics.

Back in the fall, Msdi coauthored an article on the topic and provided information on this approach. (See the article below.)

Read More: Optimizing Vancomycin Therapy: A Review of AUC Calculation Techniques


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.